| For: | Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3475-3484 [PMID: 24707130 DOI: 10.3748/wjg.v20.i13.3475] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i13/3475.htm |
| Number | Citing Articles |
| 1 |
Paula Sousa, Paula Ministro, Alessandro Armuzzi, Axel Dignass, Marte Lie Høivik, Manuel Barreiro-de Acosta, Stephan Vavricka, Rogério Saad-Hossne, Paulo Gustavo Kotze, Laurent Peyrin-Biroulet, Fernando Magro. Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. Digestive and Liver Disease 2021; 53(12) doi: 10.1016/j.dld.2021.05.038
|
| 2 |
M Cavaco, J Goncalves. Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims. Clinical Pharmacology & Therapeutics 2017; 102(4) doi: 10.1002/cpt.605
|
| 3 |
William J. Sandborn, Douglas C. Wolf, Gordana Kosutic, Gerry Parker, Stefan Schreiber, Scott D. Lee, Bincy Abraham, Anita Afzali, Razvan I. Arsenescu, Alexandra Gutierrez, Marshall Spearman, Jason Coarse, Brian G. Feagan. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol. Inflammatory Bowel Diseases 2017; 23(7) doi: 10.1097/MIB.0000000000001100
|
| 4 |
Marla C. Dubinsky, Becky L. Phan, Namita Singh, Shervin Rabizadeh, Diane R. Mould. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients. The AAPS Journal 2017; 19(1) doi: 10.1208/s12248-016-9994-y
|
| 5 |
Robert A. Mitchell, Constantin Shuster, Neal Shahidi, Cherry Galorport, Mari L. DeMarco, Gregory Rosenfeld, Robert A. Enns, Brian Bressler. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Canadian Journal of Gastroenterology and Hepatology 2016; 2016 doi: 10.1155/2016/5203898
|
| 6 |
Maria A.V. Willrich, David L. Murray, Melissa R. Snyder. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Translational Research 2015; 165(2) doi: 10.1016/j.trsl.2014.09.006
|
| 7 |
Laura Wilson, Stephanie Tuson, Lufang Yang, Dustin Loomes. Real-World Use of Azathioprine Metabolites Changes Clinical Management of Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology 2021; 4(3) doi: 10.1093/jcag/gwaa005
|
| 8 |
Vu Q. Nguyen, Kristin Eden, Holly A. Morrison, Megan B. Sammons, Kristin K. Knight, Siena Sorrentino, Rebecca M. Brock, Douglas J. Grider, Irving C. Allen, Dario Sorrentino. Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.655887
|
| 9 |
Qianhui Zou, Xin Zhang, Xiaoshuang Liu, Yitong Li, Qiaoli Tan, Qin Dan, Tian Yuan, Xuebo Liu, Rui Hai Liu, Zhigang Liu. Ficus caricapolysaccharide attenuates DSS-induced ulcerative colitis in C57BL/6 mice. Food & Function 2020; 11(7) doi: 10.1039/D0FO01162B
|
| 10 |
María López-Ibáñez, Ignacio Marín-Jiménez. Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2016; 39(4) doi: 10.1016/j.gastre.2016.03.003
|
| 11 |
Polina Zalizko, Juris Stefanovics, Jelizaveta Sokolovska, Natalia Paramonova, Evija Klavina, Renars Erts, Vita Rovite, Janis Klovins, Aldis Pukitis. Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population. Therapeutic Advances in Gastroenterology 2020; 13 doi: 10.1177/1756284820937426
|
| 12 |
Carlos Fernandes, Mariangela Allocca, Silvio Danese, Gionata Fiorino. Progress With Anti-Tumor Necrosis Factor Therapeutics for the Treatment of Inflammatory Bowel Disease. Immunotherapy 2015; 7(2) doi: 10.2217/imt.14.105
|
| 13 |
Andrea Guba, Patrícia Kováts, Zoltán A. Mezei, Mária Papp, Éva Csősz, Gergő Kalló. Analysis of Azathioprine Metabolites in Autoimmune Hepatitis Patient Blood—Method Development and Validation. International Journal of Molecular Sciences 2024; 25(20) doi: 10.3390/ijms252011233
|
| 14 |
Konstantinos Papamichael, Ann Gils, Paul Rutgeerts, Barrett G. Levesque, Séverine Vermeire, William J. Sandborn, Niels Vande Casteele. Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD. Inflammatory Bowel Diseases 2015; 21(1) doi: 10.1097/MIB.0000000000000202
|
| 15 |
Graham Cope. Managing ulcerative colitis and Crohn's disease. Nursing and Residential Care 2014; 16(12) doi: 10.12968/nrec.2014.16.12.687
|
| 16 |
Marla C. Dubinsky. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017; 129(5) doi: 10.1080/00325481.2017.1319730
|
| 17 |
Mohammad F. Rabbi, Nour Eissa, Peris M. Munyaka, Laëtitia Kermarrec, Omar Elgazzar, Ehsan Khafipour, Charles N. Bernstein, Jean Eric Ghia. Reactivation of Intestinal Inflammation Is Suppressed by Catestatin in a Murine Model of Colitis via M1 Macrophages and Not the Gut Microbiota. Frontiers in Immunology 2017; 8 doi: 10.3389/fimmu.2017.00985
|
| 18 |
Yoko Yokoyama, Kenji Watanabe, Hiroaki Ito, Masakazu Nishishita, Koji Sawada, Yusuke Okuyama, Kazuichi Okazaki, Hisao Fujii, Hiroshi Nakase, Tsutomu Masuda, Ken Fukunaga, Akira Andoh, Shiro Nakamura. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. Cytotherapy 2015; 17(5) doi: 10.1016/j.jcyt.2015.02.007
|
| 19 |
Carlos Taxonera, Marisa Iborra, Marta Maia Bosca-Watts, Saioa Rubio, Óscar Nantes, Rebeca Higuera, Federico Bertoletti, Pilar Martínez-Montiel, Mónica Sierra-Ausin, Noemí Manceñido, José Lázaro Pérez-Calle, Alicia Algaba, David Olivares, Cristina Alba. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. Current Medical Research and Opinion 2019; 35(7) doi: 10.1080/03007995.2019.1579557
|
| 20 |
Tomasz J. Ślebioda, Zbigniew Kmieć. Tumour Necrosis Factor Superfamily Members in the Pathogenesis of Inflammatory Bowel Disease. Mediators of Inflammation 2014; 2014 doi: 10.1155/2014/325129
|
| 21 |
Cindy C. Y. Law, Saranya Sasidharan, Rodrigo Rodrigues, Deanna D. Nguyen, Jenny Sauk, John Garber, Cosmas Giallourakis, Ramnik Xavier, Hamed Khalili, Vijay Yajnik, Ashwin N. Ananthakrishnan. Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations. Inflammatory Bowel Diseases 2016; 22(9) doi: 10.1097/MIB.0000000000000870
|
| 22 |
James Akingbasote, Sandra Szlapinski, Elora Hilmas, Patrik Miller, Natalie Rine. Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology. 2022; doi: 10.1007/978-3-031-12398-6_13
|
| 23 |
JAIME LUBASCHER C.. ERRORES FRECUENTES EN EL DIAGNÓSTICO Y TRATAMIENTO DE LOS PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL. Revista Médica Clínica Las Condes 2015; 26(5) doi: 10.1016/j.rmclc.2015.08.004
|
| 24 |
Sophie Steeland, Leen Puimège, Roosmarijn E. Vandenbroucke, Filip Van Hauwermeiren, Jurgen Haustraete, Nick Devoogdt, Paco Hulpiau, Geert Leroux-Roels, Debby Laukens, Philip Meuleman, Martine De Vos, Claude Libert. Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1. Journal of Biological Chemistry 2015; 290(7) doi: 10.1074/jbc.M114.617787
|
| 25 |
Marco Pelin, Elena Genova, Laura Fusco, Monzer Marisat, Ute Hofmann, Diego Favretto, Marianna Lucafò, Andrea Taddio, Stefano Martelossi, Alessandro Ventura, Gabriele Stocco, Matthias Schwab, Giuliana Decorti. Pharmacokinetics and pharmacodynamics of thiopurines in an in vitro model of human hepatocytes: Insights from an innovative mass spectrometry assay. Chemico-Biological Interactions 2017; 275 doi: 10.1016/j.cbi.2017.08.009
|
| 26 |
Ana Casajús, Pablo Zubiaur, Marta Méndez, Diana Campodónico, Antía Gómez, Marcos Navares-Gómez, Gonzalo Villapalos-García, Paula Soria-Chacartegui, Jesús Novalbos, Manuel Román, Gina Mejía-Abril, Dolores Ochoa, Francisco Abad-Santos. Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers. Advances in Therapy 2022; 39(4) doi: 10.1007/s12325-022-02067-8
|
| 27 |
María López-Ibáñez, Ignacio Marín-Jiménez. Niveles de fármaco y anticuerpos antifármaco en el manejo clínico del paciente con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2016; 39(4) doi: 10.1016/j.gastrohep.2015.09.012
|
| 28 |
Dario Sorrentino, Vu Nguyen, Carl Henderson, Adegabenga Bankole. Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases. Inflammatory Bowel Diseases 2016; 22(10) doi: 10.1097/MIB.0000000000000867
|
| 29 |
Shiyang Li, Wei Guo, Meichao Zhang, Mingyong Zeng, Haohao Wu. Microalgae polysaccharides exert antioxidant and anti-inflammatory protective effects on human intestinal epithelial cells in vitro and dextran sodium sulfate-induced mouse colitis in vivo. International Journal of Biological Macromolecules 2024; 254 doi: 10.1016/j.ijbiomac.2023.127811
|
| 30 |
M. V. Matsievich, A. O. Bueverov, M. Yu. Petrachenkova. Alternative treatment regimens in autoimmune hepatitis: how justified is their choice?. Almanac of Clinical Medicine 2018; 46(5) doi: 10.18786/2072-0505-2018-46-5-504-513
|
| 31 |
Eugènia Santacana, Lorena Rodríguez-Alonso, Ariadna Padullés, Jordi Guardiola, Francisco Rodríguez-Moranta, Katja Serra, Jordi Bas, Francisco Morandeira, Biology, Helena Colom, Núria Padullés. External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring 2018; 40(1) doi: 10.1097/FTD.0000000000000476
|
| 32 |
David Olivares, Cristina Alba, Irene Pérez, Valentín Roales, Enrique Rey, Carlos Taxonera. Differences in the need for adalimumab dose optimization between Crohn�s disease and ulcerative colitis. Revista Española de Enfermedades Digestivas 2019; 111 doi: 10.17235/reed.2019.6148/2018
|
| 33 |
Shivani Deswal, Anshu Srivastava. Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review. Journal of Clinical and Experimental Hepatology 2017; 7(1) doi: 10.1016/j.jceh.2017.01.115
|
| 34 |
Ronaldo Teixeira da Silva Júnior, Jonathan Santos Apolonio, Jessica Oliveira de Souza Nascimento, Bruna Teixeira da Costa, Luciano Hasimoto Malheiro, Marcel Silva Luz, Lorena Sousa de Carvalho, Cleiton da Silva Santos, Fabrício Freire de Melo. Crohn's disease and clinical management today: How it does?. World Journal of Methodology 2023; 13(5): 399-413 doi: 10.5662/wjm.v13.i5.399
Abstract(1026) |
Core Tip(1004) |
Full Article(HTML)(6418)
|
Full Article (PDF)-2799K(403)
|
Full Article with Cover (PDF)-3053K(321)
|
Full Article (Word)-2230K(44)
|
Full Article (XML)-263K(174)
|
Audio-289K(47)
|
Peer-Review Report-182K(169)
|
Answering Reviewers-53K(179)
|
Times Cited (14)
|
Total Visits (8110)
|
Open
|
| 35 |
Ryan Ungaro, Saurabh Mehandru, Patrick B Allen, Laurent Peyrin-Biroulet, Jean-Frédéric Colombel. Ulcerative colitis. The Lancet 2017; 389(10080) doi: 10.1016/S0140-6736(16)32126-2
|
| 36 |
Tomer Adar, Shimon Shteingart, Ami Ben-Ya’acov, Ariella Bar-Gill Shitrit, Dan M. Livovsky, Shimrit Shmorak, Mahmud Mahamid, Bernardo Melamud, Fiona Vernea, Eran Goldin. The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications. Digestive Diseases and Sciences 2016; 61(7) doi: 10.1007/s10620-016-4047-z
|
| 37 |
Timur Liwinski, Christoph Schramm. Autoimmune hepatitis — update on clinical management in 2017. Clinics and Research in Hepatology and Gastroenterology 2017; 41(6) doi: 10.1016/j.clinre.2017.07.002
|
| 38 |
Scott D. Lee, Raina Shivashankar, Daniel Quirk, Haiying Zhang, Jean-Baptiste Telliez, John Andrews, Amy Marren, Arnab Mukherjee, Edward V. Loftus. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. Journal of Clinical Gastroenterology 2021; 55(3) doi: 10.1097/MCG.0000000000001396
|
| 39 |
Walter Reinisch, Edouard Louis, Silvio Danese. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Review of Gastroenterology & Hepatology 2015; 9(sup1) doi: 10.1586/17474124.2015.1091306
|
| 40 |
Vini Deora, Justin Kozak, Mohamed El‐Kalla, Hien Q. Huynh, Wael El‐Matary. Therapeutic drug monitoring was helpful in guiding the decision‐making process for children receiving infliximab for inflammatory bowel disease. Acta Paediatrica 2017; 106(11) doi: 10.1111/apa.14008
|
| 41 |
Johanna R. Mora, Robert Wong, Mehmooda Shaikh, Margarita Askelson. Analysis of the Immunogenicity from Abatacept‐Treated Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials. ACR Open Rheumatology 2022; 4(2) doi: 10.1002/acr2.11375
|
| 42 |
Filipa Silva-Ferreira, Joana Afonso, Pedro Pinto-Lopes, Fernando Magro. A Systematic Review on Infliximab and Adalimumab Drug Monitoring. Inflammatory Bowel Diseases 2016; 22(9) doi: 10.1097/MIB.0000000000000855
|
| 43 |
Michael K Zheng, David Q Shih, Gary C Chen. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World Journal of Gastroenterology 2017; 23(11): 1932-1943 doi: 10.3748/wjg.v23.i11.1932
|
| 44 |
Shubham Jain, Suhas Udgirkar, Qais Contractor, Pravin Rathi, Prasanta Debnath, Sujit Nair. Thiopurine-induced Myelosuppression with Severe Sepsis in a Patient with Crohn's Disease: A Case Report
. Indian Journal of Critical Care Medicine 2021; 25(2) doi: 10.5005/jp-journals-10071-23738
|
| 45 |
Su-Jeong Oh, Yoojin Seo, Ji-Su Ahn, Ye Young Shin, Ji Won Yang, Hyoung Kyu Kim, Jin Han, Natalia P. Mishchenko, Sergey A. Fedoreyev, Valentin A. Stonik, Hyung-Sik Kim. Echinochrome A Reduces Colitis in Mice and Induces In Vitro Generation of Regulatory Immune Cells. Marine Drugs 2019; 17(11) doi: 10.3390/md17110622
|